Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.

OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

Sam Altman, the CEO of OpenAI, has announced a shift in his previously critical perspective on President Donald Trump. Newsweek has contacted OpenAI and the White House for comment via email.

Sam Altman's comments came amid a flurry of online exchanges between himself, Musk, and Microsoft over the $500 billion Stargate Project announced by Trump.

Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in funding to support its research. The Financial Times today cited sources as saying that Sam Altman is participating in the investment. He previously provided the initial $180 million funding round that helped launch Retro.

"I genuinely respect your accomplishments and think you are the most inspiring entrepreneur of our time," Altman wrote in an X post to Musk.

Donald Trump says his big new AI initiative is a victory for America. Guess who the real winner is.

Musk has raised questions on project Stargate, the $500bn AI project. This lead to a verbal spat between him and Sam Altman.

Musk, the billionaire SpaceX and Tesla CEO, took shots this week at Stargate, Trump's highly touted project, and its partners.

President Trump dismissed Elon Musk’s doubts about the $500 billion “Stargate” AI project, citing personal differences. OpenAI CEO Sam Altman defended the project and invited Musk to visit the construction site.

We recently compiled a list of the 10 Trending AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Palo Alto Networks, Inc. (NASDAQ:PANW) stands against the other AI stocks.